SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

LUPIN

BSE: 500257 20 May 2025
Healthcare
₹ 1978.4
Lupin Ltd specializes in Pharmaceuticals within the Healthcare sector.

LUPIN - Share Price & Details

Market Cap
₹94,360
High /Low
2,403 / 1,493
Stock P/E
28.8
Book Value
₹377.0
Dividend Yield
0.39
ROCE
21.5
ROE
₹20.8
Face Value
2.0
PEG Ratio
0.52
EVEBITDA
₹17.6
Debt
5,448
CMP / FCF
62.7
Debt to equity
₹0.32
NP Ann
3,306
High price all time
2,403
Piotroski score
₹6.0
Graham Number
781.0
No. Eq. Shares
45.7
Net CF
₹560
Net profit
3,306
Price to book value
5.49
Interest Coverage
₹14.6
Low price all time
52.5
Industry PE
30.8
Reserves
₹17,112
Free Cash Flow
₹1,347

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
Shyama Computronics and Servic0.700.190.61NA4.1732.1
Triochem Products Ltd.,4.590.88NA3.600
LUPIN LTD.45344.612913.544856.728.2194,36028.8
Zydus Lifesciences Limited25,934.004,706.0025,159.004.689162320.2
AUROBINDO PHARMA LTD.29,708.904,720.5029,166.308.137089920.0

Peer Comparison Chart


About LUPIN

Lupin Ltd, with Security Code 500257, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Stocks to buy in 2025: Lupin, Piramal Pharma among 5 stocks that could give 10-20% return

(19 May 2025)
Brokerages have turned selectively bullish on several mid- and large-cap stocks across sectors, highlighting strong fundamentals,...
Read more →

Analysts Are Updating Their Lupin Limited (NSE:LUPIN) Estimates After Its Annual Results

(19 May 2025)
Last week saw the newest full-year earnings release from Lupin Limited ( NSE:LUPIN ), an important milestone in the...
Read more →

Lupin Faces Financial Challenges Amidst Growth, Adjusts Market Positioning

(19 May 2025)
Lupin has recently experienced a score adjustment reflecting changes in its financial metrics and market position.
Read more →

Lupin shares: Brokerage sees 23% upside potential, anticipates high growth with new US launches

(18 May 2025)
Nuvama Institutional Equities said Lupin Ltd has reported financial results that exceed market expectations, with revenue, EBITDA and PAT...
Read more →

Lupin Stock Closes 0.07% Lower Post Q4 Results Despite PAT Doubling to Rs 782 Crore on Strong Sales Growth

(16 May 2025)
Shares of Lupin Ltd closed marginally lower on May 15, settling at Rs 2070.00, down by 0.07%. Despite this slight dip, the pharmaceutical...
Read more →

Lupin Q4 Profit Soars 100%+ on Higher Sales - Rs 782 Cr

(16 May 2025)
Lupin's Q4 PAT surged over 100% to Rs 782 crore, driven by new products and operational efficiencies. Sales also grew to Rs 5562 crore.
Read more →